---
title: "據彭博新聞報道，諾和諾德公司為了削減成本，已停止糖尿病細胞療法的研究工作"
description: "諾和諾德公司已削減其細胞治療部門，該部門一直在努力尋找 1 型糖尿病的治療方法，彭博新聞週五援引一份聲明報道"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/260667796.md"
published_at: "2025-10-10T15:52:08.000Z"
---

# 據彭博新聞報道，諾和諾德公司為了削減成本，已停止糖尿病細胞療法的研究工作

> 諾和諾德公司已削減其細胞治療部門，該部門一直在努力尋找 1 型糖尿病的治療方法，彭博新聞週五援引一份聲明報道

彭博新聞週五報道稱，諾和諾德公司已削減其細胞治療部門，該部門一直在努力尋找 1 型糖尿病的治療方法，引用了一份聲明。

### Related Stocks

- [NVO.US - 諾和諾德公司](https://longbridge.com/zh-HK/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo set to make Wegovy pill in Ireland for markets outside US - Bloomberg News | Novo set to make Wegovy pill in Ireland for markets outside US - Bloomberg News | [Link](https://longbridge.com/zh-HK/news/275772102.md) |
| Novo Nordisk Aims To Start Selling Its Weight-Loss Blockbuster Wegovy In Vials - Bloomberg News | NOVO NORDISK AIMS TO START SELLING ITS WEIGHT-LOSS BLOCKBUSTER WEGOVY IN VIALS - BLOOMBERG NEWS | [Link](https://longbridge.com/zh-HK/news/275654518.md) |
| Assessing Novo Nordisk (CPSE:NOVO B) Valuation After Recent Share Price Pullback And Mixed Returns | Novo Nordisk (CPSE:NOVO B) has experienced mixed returns, with a recent 1.7% gain but a 17.6% decline over the past mont | [Link](https://longbridge.com/zh-HK/news/275941659.md) |
| Activist Third Point Builds Indra Stake, Urges Board To Buy Em&E - Bloomberg News | ACTIVIST THIRD POINT BUILDS INDRA STAKE, URGES BOARD TO BUY EM&E - BLOOMBERG NEWS | [Link](https://longbridge.com/zh-HK/news/276068592.md) |
| First Brands Mulls Placing Some Units Into Chapter 7 Liquidation - Bloomberg News | FIRST BRANDS MULLS PLACING SOME UNITS INTO CHAPTER 7 LIQUIDATION - BLOOMBERG NEWS | [Link](https://longbridge.com/zh-HK/news/275936932.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。